All In Biotech

Drug Trial Radar · NCT06066827

Hair Regeneration in Androgenetic Alopecia

Hair Regeneration in Androgenetic Alopecia Using Secretome of Adipose-derived Stem Cells (ADSC) and Minoxidil: A Comparative Study of Three Groups

Last checked: Nov 19, 2026Latest source record: Oct 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Actual

Start

Aug 14, 2023

Primary completion

Nov 30, 2023

Study completion Nov 30, 2023

Sponsor

Lead sponsor
Dr. dr. Lili Legiawati, SpKK(K)Academic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Education, Culture, Research, and Technology, Republic of Indonesia; PT. Kimia Farma (Persero) Tbk
First posted
Oct 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 59 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This clinical trial study aims to compare the effectiveness and safety of secretome from ADSCs with minoxidil in AGA cases, to provide future reference or standard in the application of cell-based therapy and its derivatives in AGA cases. The subject of this study is androgenetic alopecia population. The main questions it aims to answer are: * Is the secretome of ADSC's effective compared to minoxidil? * Is the secretome of ADSC's safe compared to minoxidil? * Is the combination of the secretome of ADSC's and minoxidil better in safety and effectiveness compared to secretome or minoxidil alone?

Conditions

  • Androgenetic Alopecia

Interventions

  • Minoxidil TopicalDrug

    20 subjects received minoxidil only for the treatment of AGA

  • Secretome from adipose-derived stem cellsOther

    20 subjects received the injection of secretome from adipose-derived stem cells only for the treatment of AGA

  • Combination of minoxidil and secretome from adipose-derived stem cellsCombination product

    20 subjects received both minoxidil and injection of secretome from adipose-derived stem cells for the treatment of AGA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Improvement of alopecia in physical examinationTime frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
  2. Macroscopic hair growth documentedTime frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
  3. Microscopic hair growth evaluated by TrichoscopyTime frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)
  4. Microscopic hair growth evaluated by TrichoscanTime frame: Week 0 (baseline), week 4 after intervention, week 8 after intervention, week 12 (end of trial)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • RSUP Nasional Cipto Mangunkusumo

    Jakarta Pusat, DKI Jakarta, Indonesia

  • Universitas Indonesia

    Jakarta Pusat, Jakarta Special Capital Region, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.